XML 37 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Segment reporting
 12 Months Ended
Jul. 31, 2021
Segment Reporting [Abstract]  
Segment reporting

Note 17 - Segment reporting

 

The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.

 

Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal and related expenses specific to other segments’ activities are allocated to those segments.

 

Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

 

The following financial information represents the operating results of the reportable segments of the Company:

 

Year ended July 31, 2021

 

   Clinical
Laboratory
Services		   Life
Sciences
Products		   Therapeutics   Other   Consolidated 
Revenues  $86,984   $30,747   $
—
   $
—
   $117,731 
Operating costs and expenses:                         
Cost of revenues   48,179    15,975    
—
    
—
    64,154 
Research and development   615    2,559    78    
—
    3,252 
Selling, general and administrative   26,028    11,015    62    7,800    44,905 
Legal and related expenses   264    25    
—
    4,439    4,728 
Total operating costs and expenses   75,086    29,574    140    12,239    117,039 
                          
Operating income (loss)   11,898    1,173    (140)   (12,239)   692 
                          
Other income (expense)                         
Interest   (17)   37    
—
    (12)   8 
Other   (18)   7    
—
    6,916    6,905 
Foreign exchange gain   
—
    270    
—
    
—
    270 
Income (loss) before taxes  $11,863   $1,487   $(140)  $(5,335)  $7,875 
                          
Depreciation and amortization included above  $1,609   $756   $
—
   $288   $2,653 
                          
Share-based compensation included in above:                         
Selling, general and administrative   33    102    
—
   $679    814 
Cost of sales   93    
—
    
—
    
—
    93 
Total  $126   $102   $
—
   $679   $907 
                          
Capital expenditures  $3,352   $752   $
—
   $332   $4,436 

 

Year ended July 31, 2020

 

   Clinical
Laboratory
Services		   Life
Sciences
Products		   Therapeutics   Other   Consolidated 
Revenues – Services and Products  $47,964   $26,561    
—
    
—
   $74,525 
Grant income   1,496    
—
    
—
    
—
    1,496 
Total   49,460    26,561    
—
    
—
    76,021 
Operating costs and expenses::                         
Cost of revenues   38,855    13,396    
—
    
—
    52,251 
Research and development   1,509    2,190   $749    
—
    4,448 
Selling, general and administrative   23,533    10,485    
—
   $8,942    42,960 
Legal and related expenses   211    2    
—
    6,516    6,729 
Total operating costs and expenses   64,108    26,073    749    15,458    106,388 
                          
Operating (loss) income   (14,648)   488    (749)   (15,458)   (30,367)
                          
Other income (expense)                         
Interest   (36)   56    
—
    434    454 
Other   45    13    
—
    430    488 
Foreign exchange gain   
—
    905    
—
    
—
    905 
(Loss) income before taxes  $(14,639)  $1,462   $(749)  $(14,594)  $(28,520)
                          
Depreciation and amortization included above  $1,553   $964    
—
   $263   $2,780 
                          
Share-based compensation included  above:                         
Selling, general and administrative   57    74    
—
    756    887 
Cost of sales   46    
—
    
—
    
—
    46 
Total  $103   $74    
—
   $756   $933 
                          
Capital expenditures  $1,811   $322    
—
   $37   $2,170 

 

The following financial information represents the operating results of the reportable segments of the Company:

 

Year ended July 31, 2019

 

   Clinical
Laboratory Services		   Life
Sciences Products		   Therapeutics   Other   Consolidated 
Revenues  $51,115   $30,055   $
—
   $
—
   $81,170 
Operating costs, expenses and legal settlements, net:                         
Cost of revenues   44,226    13,696    
—
    
—
    57,922 
Research and development   31    2,257    887    
—
    3,175 
Selling, general and administrative   24,230    11,860    
—
    8,175    44,265 
Legal and related expenses   159    27    
—
    2,814    3,000 
Legal settlements, net   
—
    (28,925)   
—
    
—
    (28,925)
Total operating costs, expenses and legal settlements, net   68,646    (1,085)   887    10,989    79,437 
                          
Operating income (loss)   (17,531)   31,140    (887)   (10,989)   1,733 
                          
Other income (expense)                         
Interest   (64)   67    
—
    1,053    1,056 
Other   16    2    
—
    364    382 
Foreign exchange loss   
—
    (682)   
—
    
—
    (682)
Income (loss) before taxes  $(17,579)  $30,527   $(887)  $(9,572)  $2,489 
                          
Depreciation and amortization included above  $1,625   $1,221   $
—
   $190   $3,036 
                          
Share-based compensation included  above:                         
Selling, general and administrative   147    95    
—
   $697    939 
Total  $147   $95   $
—
   $697   $939 
                          
Capital expenditures  $1,374   $605   $
—
   $6,147   $8,126 

 

Geographic financial information is as follows:

 

Net Services, Products and Grant revenues from unaffiliated customers, Year ended July 31,:  2021   2020   2019 
United States  $102,602   $64,284   $68,081 
Europe   10,386    7,720    8,551 
Asia Pacific   4,744    4,017    4,538 
Total  $117,731   $76,021   $81,170 

 

Long-lived assets, at July 31,  2021   2020 
United States  $41,249   $41,946 
Europe   52    442 
Total  $41,301   $42,388 

 

The Company’s reportable segments are determined based on the services they perform and the products they sell, not on the geographic area in which they operate. The Company’s Clinical Laboratory Services segment operates 100% in the United States with all revenue derived there. The Life Sciences Products segment earns product revenue both in the United States and foreign countries. The following is a summary of the Life Sciences Products segment product revenues attributable to customers located in the United States and foreign countries for the years ended July 31,:

 

    2021     2020     2019  
United States   $ 15,617     $ 14,824     $ 16,966  
Foreign countries     15,130       11,737       13,089  
    $ 30,747     $ 26,561     $ 30,055